The FDA has approved Allergan's supplemental biologics application for Botox as a treatment for children ages 2 to 17 with upper limb spasticity.
Allergan secures FDA nod for Botox in pediatric cerebral palsy
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.